Tag: GCP non-compliance

Training Investigators on Their Regulatory Reporting Responsibilities Training Investigators on Their Regulatory Reporting Responsibilities The management of regulatory reporting in clinical trials is a critical aspect that ensures compliance with various regulatory standards and the integrity of study findings. Understanding the responsibilities that investigators hold in this area is essential for clinical operations, regulatory affairs,…

Read More “Training Investigators on Their Regulatory Reporting Responsibilities” »

Remote and DCT-Specific Considerations for Deviation Notifications Remote and DCT-Specific Considerations for Deviation Notifications As clinical trials increasingly transition to decentralized models, understanding the specific regulatory requirements surrounding protocol deviations becomes crucial. This article provides a comprehensive guide on handling deviation notifications in remote and decentralized clinical trials (DCTs). The guidelines will address the nuances…

Read More “Remote and DCT-Specific Considerations for Deviation Notifications” »

Documenting Justification When a Deviation Is Not Reported Externally In the realm of clinical trials, adherence to protocols is paramount for maintaining integrity and compliance. However, situations may arise where protocol deviations occur but are deemed not significant enough to warrant external reporting. This article guides clinical operations, regulatory affairs, and medical affairs professionals on…

Read More “Documenting Justification When a Deviation Is Not Reported Externally” »

Integrating Notification Decisions With Risk Categorization and CAPA Integrating Notification Decisions With Risk Categorization and CAPA Clinical trial centers play a vital role in conducting world wide clinical trials, ensuring that research is compliant with regulatory standards while also safeguarding participant welfare. One key aspect of this compliance is effectively managing protocol deviations and non-compliance…

Read More “Integrating Notification Decisions With Risk Categorization and CAPA” »

Templates for IRB and Health Authority Deviation Notification Letters Templates for IRB and Health Authority Deviation Notification Letters Introduction to Protocol Deviations In the conduct of clinical trials, specific protocols dictate the parameters by which a study is conducted. Successful adherence to these protocols is essential for ensuring the integrity of the study, participant safety,…

Read More “Templates for IRB and Health Authority Deviation Notification Letters” »

Case Studies: Under-Reporting of Deviations and Regulatory Consequences Case Studies: Under-Reporting of Deviations and Regulatory Consequences Clinical trials are pivotal in the development of new therapies, and protocol deviations can significantly impact the integrity and outcomes of these studies. Under-reporting of these deviations poses regulatory challenges, leading to consequences that affect clinical trial operations. This…

Read More “Case Studies: Under-Reporting of Deviations and Regulatory Consequences” »

Timelines and Content Requirements for Serious Breach Notifications In the evolving landscape of clinical trials, particularly biosimilar clinical trials, maintaining compliance with regulatory frameworks is paramount. Serious breaches, or deviations from established protocols and guidelines, can significantly impact the integrity of clinical research outcomes and the safety of participants. This article serves as a comprehensive…

Read More “Timelines and Content Requirements for Serious Breach Notifications” »

Aligning Sponsor, CRO and Site SOPs on Deviation Reporting to Regulators Aligning Sponsor, CRO and Site SOPs on Deviation Reporting to Regulators In the landscape of clinical trials, effectively navigating regulatory requirements is crucial for sponsors, Contract Research Organizations (CROs), and clinical trial sites. One of the most critical aspects of clinical trial management revolves…

Read More “Aligning Sponsor, CRO and Site SOPs on Deviation Reporting to Regulators” »

IRB/IEC Reporting Thresholds for Deviations That Impact Safety or Rights IRB/IEC Reporting Thresholds for Deviations That Impact Safety or Rights Introduction to IRB/IEC Reporting in Clinical Trials In clinical research, oversight by institutional review boards (IRBs) or ethics committees (IECs) is paramount for protecting the rights and welfare of participants. This article aims to provide…

Read More “IRB/IEC Reporting Thresholds for Deviations That Impact Safety or Rights” »

Coordinating Notifications Across FDA, EMA, MHRA and Local Ethics Bodies In the complex landscape of clinical trials, ensuring compliance with various regulatory bodies is critical for maintaining the integrity and success of a study. This article provides a detailed, step-by-step tutorial for clinical operations, regulatory affairs, and medical affairs professionals on coordinating notifications across the…

Read More “Coordinating Notifications Across FDA, EMA, MHRA and Local Ethics Bodies” »